β-centractin Inhibitors

The chemical class of β-centractin inhibitors comprises compounds that influence the protein indirectly by modulating the cytoskeletal components and associated signaling pathways. β-centractin is a protein implicated in the stabilization and organization of the cytoskeleton, which is a dynamic structure involved in numerous cellular functions, including intracellular transport, cellular division, and maintenance of cell shape. Therefore, the compounds listed can affect β-centractin's function by altering the dynamics and integrity of the cytoskeletal framework.

The first group of compounds, including nocodazole, colchicine, vinblastine, and paclitaxel, interacts with microtubules. Nocodazole and colchicine disrupt microtubule polymerization, while taxol and paclitaxel stabilize microtubules. These alterations in microtubule dynamics can impact β-centractin's ability to associate with microtubules and perform its functions, which include the regulation of microtubule-dependent vesicle transport. The second group of compounds, such as cytochalasin D, swinholide A, jasplakinolide, and latrunculin A, targets the actin cytoskeleton. Cytochalasin D and latrunculin A disrupt actin polymerization, whereas swinholide A severs actin filaments and jasplakinolide stabilizes them. These changes can influence β-centractin's interaction with actin, possibly affecting processes where actin-microtubule crosslinking is essential. The remaining compounds, blebbistatin, Y-27632, and ML-7, inhibit specific proteins that regulate cytoskeletal dynamics.